| Spinal Muscular Atrophy
Spinraza vs Evrysdi
Side-by-side clinical, coverage, and cost comparison for spinal muscular atrophy.Deep comparison between: Spinraza vs Evrysdi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEvrysdi has a higher rate of injection site reactions vs Spinraza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Evrysdi but not Spinraza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Spinraza
Evrysdi
At A Glance
Intrathecal injection
Every 4 months (maintenance)
Antisense oligonucleotide (ASO)
Oral
Daily
SMN2 splicing modifier
Indications
- Spinal Muscular Atrophy
- Spinal Muscular Atrophy
Dosing
Spinal Muscular Atrophy - Low Dose Regimen Loading: 12 mg intrathecally every 14 days for 3 doses, then a fourth 12 mg dose 30 days after the third; maintenance: 12 mg once every 4 months.
Spinal Muscular Atrophy - High Dose Regimen Loading: 50 mg intrathecally followed by a second 50 mg dose 14 days later; maintenance: 28 mg once every 4 months.
Spinal Muscular Atrophy Once daily orally with or without food: <2 months 0.15 mg/kg; 2 months to <2 years 0.2 mg/kg; >=2 years weighing <20 kg 0.25 mg/kg; >=2 years weighing >=20 kg 5 mg (oral solution or tablet).
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Lower respiratory infection, constipation (infantile-onset SMA); pyrexia, headache, vomiting, back pain (later-onset SMA)
Serious Thrombocytopenia, coagulation abnormalities, renal toxicity, atelectasis
Postmarketing Meningitis, hydrocephalus, aseptic meningitis, angioedema, urticaria, rash, arachnoiditis
Most common (>=10%) - Later-onset SMA fever, diarrhea, rash
Most common (>=10%) - Infantile-onset SMA fever, diarrhea, rash, upper respiratory tract infection, lower respiratory tract infection, constipation, vomiting, cough
Pharmacology
Antisense oligonucleotide (ASO) that increases exon 7 inclusion in SMN2 mRNA transcripts, restoring production of full-length SMN protein to treat SMA caused by chromosome 5q mutations leading to SMN protein deficiency.
Risdiplam is an SMN2 splicing modifier that increases exon 7 inclusion in SMN2 mRNA transcripts, resulting in increased production of full-length SMN protein in the brain to treat spinal muscular atrophy caused by chromosome 5q mutations leading to SMN protein deficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Spinraza
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Evrysdi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Spinraza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Evrysdi
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Spinraza
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Evrysdi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Biogen $0 Drug/Procedure Copay Program: SpinrazaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Evrysdi Co-pay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SpinrazaView full Spinraza profile
EvrysdiView full Evrysdi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.